X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (16112) 16112
Newsletter (2921) 2921
Newspaper Article (420) 420
Magazine Article (169) 169
Book Chapter (50) 50
Dissertation (31) 31
Reference (20) 20
Government Document (18) 18
Conference Proceeding (9) 9
Publication (6) 6
Trade Publication Article (6) 6
Transcript (5) 5
Book / eBook (3) 3
Journal / eJournal (2) 2
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cox-2 inhibitors (12889) 12889
humans (6200) 6200
animals (5375) 5375
cox-2 (5169) 5169
male (3772) 3772
cyclooxygenase-2 (3174) 3174
research (3123) 3123
female (2904) 2904
inflammation (2885) 2885
cancer (2758) 2758
analysis (2649) 2649
cyclooxygenase 2 - metabolism (2541) 2541
pharmacology & pharmacy (2511) 2511
mice (2452) 2452
celecoxib (2397) 2397
expression (2330) 2330
rats (2035) 2035
nonsteroidal antiinflammatory drugs (1857) 1857
oncology (1814) 1814
apoptosis (1753) 1753
prostaglandins (1702) 1702
nitric oxide (1656) 1656
biochemistry & molecular biology (1637) 1637
cyclooxygenase 2 (1493) 1493
care and treatment (1452) 1452
middle aged (1420) 1420
enzymes (1419) 1419
cyclooxygenase inhibitors - pharmacology (1358) 1358
nonsteroidal anti-inflammatory drugs (1259) 1259
inhibition (1202) 1202
cyclooxygenase 2 - genetics (1195) 1195
cyclooxygenase 2 inhibitors - pharmacology (1190) 1190
adult (1167) 1167
cell biology (1160) 1160
aged (1159) 1159
health aspects (1156) 1156
chemistry, medicinal (1135) 1135
drugs (1118) 1118
physiological aspects (1048) 1048
membrane proteins (1022) 1022
activation (1001) 1001
prevention (991) 991
nf-kappa-b (974) 974
cyclooxygenase (972) 972
cells (966) 966
gene expression (959) 959
dose-response relationship, drug (957) 957
sulfonamides - pharmacology (953) 953
cell line, tumor (948) 948
mitogens (920) 920
immunohistochemistry (903) 903
proteins (885) 885
aspirin (881) 881
cyclooxygenase 2 inhibitors (876) 876
risk factors (867) 867
oxidative stress (850) 850
neurosciences (848) 848
drug therapy (822) 822
osteoarthritis (820) 820
immunology (814) 814
prostaglandins e (814) 814
rofecoxib (796) 796
anti-inflammatory agents, non-steroidal - pharmacology (792) 792
prostaglandin-endoperoxide synthases - metabolism (792) 792
pharmaceutical industry (774) 774
indomethacin (753) 753
anti-inflammatory agents, non-steroidal - adverse effects (741) 741
macrophages (737) 737
universities and colleges (736) 736
in-vitro (734) 734
anti-inflammatory agents, non-steroidal - therapeutic use (723) 723
disease models, animal (716) 716
rats, sprague-dawley (716) 716
nitric-oxide synthase (699) 699
oncology, experimental (694) 694
nsaids (688) 688
pain (685) 685
rodents (685) 685
dinoprostone - metabolism (683) 683
cytokines (682) 682
rheumatoid-arthritis (682) 682
cyclooxygenase inhibitors - therapeutic use (678) 678
rats, wistar (677) 677
medical research (675) 675
cell line (664) 664
risk (664) 664
cyclooxygenase 2 inhibitors - therapeutic use (661) 661
tumors (659) 659
cox-2 inhibitor (658) 658
gene-expression (648) 648
rna (642) 642
cells, cultured (641) 641
angiogenesis (639) 639
pyrazoles - pharmacology (633) 633
inhibitors (631) 631
medicine, research & experimental (630) 630
apoptosis - drug effects (625) 625
interleukins (606) 606
nitric-oxide (596) 596
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (19451) 19451
Chinese (117) 117
German (105) 105
Japanese (78) 78
French (46) 46
Portuguese (32) 32
Spanish (32) 32
Korean (18) 18
Polish (12) 12
Russian (11) 11
Italian (7) 7
Czech (6) 6
Slovak (4) 4
Norwegian (2) 2
Romanian (2) 2
Croatian (1) 1
Dutch (1) 1
Hungarian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Pharmacoepidemiology and drug safety, ISSN 1053-8569, 2017, Volume 26, Issue 10, pp. 1141 - 1148
...‐inflammatory drugs (NSAIDs) with proton pump inhibitors (PPIs) and selective COX‐2 inhibitors, with or without PPIs compared with conventional NSAIDs. Methods A case... 
proton pump inhibitors | bleeding | gastrointestinal toxicity | perforation | selective COX‐2 inhibitors | ulcers | conventional NSAIDs | selective COX-2 inhibitors | RHEUMATOID-ARTHRITIS | CARDIOVASCULAR EVENTS | NONSELECTIVE NSAIDS | CELECOXIB | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | CONTROLLED TRIALS | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | HIGH-RISK | CYCLOOXYGENASE-2 INHIBITORS | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | OSTEOARTHRITIS | Age Factors | Humans | Middle Aged | Peptic Ulcer - prevention & control | Male | Peptic Ulcer - epidemiology | Gastrointestinal Hemorrhage - epidemiology | Case-Control Studies | Cyclooxygenase 2 Inhibitors - adverse effects | Peptic Ulcer Perforation - epidemiology | Pain - drug therapy | Pain Management - adverse effects | Aged, 80 and over | Female | Odds Ratio | Peptic Ulcer - complications | Risk Factors | Pain Management - methods | Proton Pump Inhibitors - therapeutic use | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Peptic Ulcer Perforation - prevention & control | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Aged | Peptic Ulcer - chemically induced | Peptic Ulcer Perforation - etiology | COX-2 inhibitors | Proton pump inhibitors | Nonsteroidal anti-inflammatory drugs | Drugs | Antiinflammatory agents | Control methods | Adjustment | Toxicity | Perforation | Pharmacology | Inflammation | Regression analysis | Patients | Risk factors | Bleeding | Confidence intervals | Inhibitors | Ulcers | Cyclooxygenase-2 | Health risk assessment | Original Report | Original Reports
Journal Article
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 2016, Volume 14, Issue 6, pp. 809 - 815.e1
Journal Article
Journal Article
Molecules (Basel, Switzerland), ISSN 1420-3049, 2018, Volume 23, Issue 3, p. 685
Journal Article
Nature communications, ISSN 2041-1723, 2017, Volume 8, Issue 1, pp. 1 - 14
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2007, Volume 369, Issue 9573, pp. 1621 - 1626
...) inhibitor or a non-steroidal anti-inflammatory drug (NSAID) with a proton-pump inhibitor (PPI). These two treatments have similar effectiveness, but they are insufficient for protection of patients at very high risk for ulcer bleeding... 
Internal Medicine | ESOMEPRAZOLE | MEDICINE, GENERAL & INTERNAL | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | NSAID | CYCLOOXYGENASE-2 INHIBITORS | ARTHRITIS PATIENTS | NAPROXEN | COMPLICATIONS | HELICOBACTER-PYLORI | PEPTIC-ULCER | CELECOXIB | Pyrazoles - therapeutic use | Humans | Esomeprazole - adverse effects | Male | Secondary Prevention | Osteoarthritis - drug therapy | Esomeprazole - therapeutic use | Peptic Ulcer Hemorrhage - prevention & control | Female | Drug Therapy, Combination | Pyrazoles - adverse effects | Anti-Ulcer Agents - therapeutic use | Double-Blind Method | Proton Pump Inhibitors | Risk Factors | Anti-Ulcer Agents - adverse effects | Peptic Ulcer Hemorrhage - chemically induced | Treatment Outcome | Celecoxib | Peptic Ulcer Hemorrhage - therapy | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Sulfonamides - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Sulfonamides - adverse effects | Aged | Cyclooxygenase Inhibitors - adverse effects | Cyclooxygenase Inhibitors - therapeutic use | Prevention | Complications and side effects | COX-2 inhibitors | Relapse | Gastrointestinal bleeding | Peptic ulcer | Proton pump inhibitors | Dosage and administration | Drug therapy | Diseases | Drugs | Medical research | Physical examinations | Hospitals | Analgesics | Ulcers | Terminal illnesses | Clinical trials | Pharmaceuticals
Journal Article
Journal Article